Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has entered into a licensing agreement with U.S. firm Belenos Biosciences Inc. Under the agreement, Belenos gains exclusive global rights to develop, manufacture, and commercialize Keymed’s in-house developed bispecific antibodies (BsAbs), CM512 and CM536, excluding Greater China.
Belenos will make an upfront and near-term payment of USD 15 million to Keymed and is further committed to potential total milestone payments of USD 170 million, coupled with tiered royalties based on net sales. Additionally, Keymed will acquire a 30.01% equity stake in Belenos, which will assume responsibility for all development, regulatory, and commercial costs associated with both CM512 and CM536.- Flcube.com
